Clinical trial
Neuromodulation for a Novel OCD Biomarker and Treatment
NCT05994053 is registered in ClinicalTrials.gov with Boston University Charles River Campus as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Neuromodulation for a Novel OCD Biomarker and Treatment
- Lead sponsor
- Boston University Charles River Campus
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- July 1, 2024
- Completion date
- August 31, 2027
- Enrollment
- 90 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ocd